Study of MEK162 for Children With Low-Grade Gliomas

• ClinicalTrials.gov Identifier: NCT02285439
• Recruitment Status: Active, not recruiting
• First Posted: November 7, 2014
• Last Update Posted: October 3, 2023
• Sponsor: Children's Hospital Los Angeles
• Collaborator: Dana-Farber Cancer Institute
• Information provided by (Responsible Party): Nathan Robison, M.D., Children's Hospital Los Angeles

Study Description

Brief Summary:

The goal of this clinical trial is to study the drug MEK162 in children with a brain tumor call low-grade glioma, as well as in children with other tumors in which a specific growth signal is abnormally turned on. The main questions it aims to answer are:

What is the correct dose of MEK162 in children? What are the side effects of MEK162 in children? Is MEK162 effective in children with low-grade glioma?

Participants on the study receive MEK162 by mouth twice daily for up to 2 years.

Condition or disease	Intervention/treatment	Phase
Low-Grade Gliomas; Malignant Neoplasms, Brain; Soft Tissue Neoplasms	Drug: MEK162	Phase 1; Phase 2

Detailed Description:

PROTOCOL SUMMARY:

Phase 1: Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and toxicity profile.

Phase 2: Patients with recurrent or progressive tumors signaling through the ras/raf pathway after standard up-front therapy will be treated in three strata to define the activity of MEK162.

Stratum 1: Pediatric patients with recurrent or progressive low-grade glioma (LGG) characterized by a BRAF truncated fusion (KIAA1549 and similar translocations).

Stratum 2: Pediatric patients with neurofibromatosis type 1 (NF1) and recurrent or progressive LGG.

Stratum 3: Pediatric patients with recurrent or progressive tumors thought to involve the ras/raf/MAP pathway but not included in strata 1 or 2. This includes any LGG not included in strata 1 or 2 (i.e., any LGG without a BRAF truncated fusion in a patient without NF1), any tumor other than LGG in a patient with NF1, and any other tumor with a known activating BRAF, NRAS or KRAS mutation.

Target validation phase: Patient enrolled on the phase 2 component (any stratum) for whom tumor biopsy or resection is clinically indicated. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Samples will be analyzed for concentration of drug and target inhibition.

Length of therapy:

Protocol treatment will last approximately 48 weeks from the start of MEK162 in the absence of significant toxicity. Treatment will be administered based on the dose escalation schema for phase 1. Patients in the phase 2 component of the trial will also receive a planned 48 weeks of therapy. Those undergoing planned tumor resection based on clinical criteria will be eligible to receive 7-21 days of treatment with MEK162 prior to the surgical procedure.

Imaging to assess response will be obtained at the end of cycle 1 (+/- 1 week), at the end of cycle 3 (+/- 2 weeks) and after every three cycles thereafter (+/- 2 weeks). A cycle will consist of 28 days (+/- 3 days) and MEK162 will be given continuously. Patients deriving benefit may continue therapy beyond study completion but all protocol specific evaluations (other than survival or progression) will conclude after one year. All patients will be followed with progression as the end point.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 105 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase I-II Study of MEK 162 for Children With Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
• Actual Study Start Date: May 4, 2016
• Actual Primary Completion Date: November 2, 2022
• Estimated Study Completion Date: November 30, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Phase 1; Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the MTD, DLT, and toxicity profile.	Drug: MEK162; • MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped; Other Names: ARRY 438162; Binimetinib
Experimental: Phase 2; Children with recurrent tumors signaling through the Ras/Raf pathway will be treated in 3 strata to define the activity of MEK162. S1: Children with LGG characterized by a BRAF truncated fusion (KIAA1549 and similar translocations). S2: Children with NF1 and LGG. S 3: Children with tumors involving the Ras/Raf pathway not included in strata 1 or 2.	Drug: MEK162; • MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped; Other Names: ARRY 438162; Binimetinib
Experimental: Target Validation; Patients eligible for phase 2 (any stratum) for whom tumor biopsy or resection is clinically indicated may be enrolled on the target validation arm. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Tumor sample will be analyzed for drug concentration and target inhibition.	Drug: MEK162; • MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped; Other Names: ARRY 438162; Binimetinib

Outcome Measures

Primary Outcome Measures :

1. Response rate [ Time Frame: Study duration (up to 3 years) ]
   Phase 2: Response rate (strata 1 and 2)

Secondary Outcome Measures :

1. Survival [ Time Frame: Study duration (up to 3 years) ]
   12-month progression-free and overall survival (strata 1 and 2)

Other Outcome Measures:

1. Stratum 3 Response Rate [ Time Frame: Study duration (up to 3 years) ]
   Response rate for patients in stratum 3 (other tumors with known or presumed activation of the ras/raf/MEK/ERK pathway, not included in strata 1 or 2).
2. Tumor response as a function of BRAF tumoral genotype [ Time Frame: Study duration (up to 3 years) ]
   Tumor response as a function of BRAF tumoral genotype.
3. Target Validation (Intra-tumoral MEK162 concentration, and intra-tumoral inhibition of downstream mediators of the ras/raf/MEK/ERK pathway (e.g., pERK). [ Time Frame: Study duration (up to 3 years) ]
   Target Validation: Intra-tumoral MEK162 concentration, and intra-tumoral inhibition of downstream mediators of the ras/raf/MEK/ERK pathway (e.g., pERK).

Eligibility Criteria

• Ages Eligible for Study: 1 Year to 18 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Patients with recurrent or progressive disease, as defined in the following three strata below, will be eligible. For eligibility determination, tumor imaging from at least two time-points must be available to document radiographic progression or recurrence. Patients with non-progressive refractory tumors will not be eligible.

• Stratum 1: patients with LGG with a BRAF truncated fusion that is measurable in at least two dimensions on imaging.
• Stratum 2: patients with NF1 and LGG that is measurable in at least two dimensions on imaging.
• Stratum 3: Pediatric patients with a recurrent or progressive tumor thought to involve the Ras/Raf/ERK pathway but not included in strata 1 or 2 that is measurable in at least two dimensions on imaging. This includes any LGG not included in strata 1 or 2 (i.e., any LGG without a BRAF truncated fusion in a patient without NF1), any tumor other than LGG in a patient with NF1, and any other tumor with a documented activating BRAF, NRAS, or KRAS mutation.
• Stratum 4 (surgical arm, target validation): Patients who meet criteria for stratum 1, 2, or 3 for whom tumor biopsy and/or resection is clinically indicated.
• Tumor tissue for correlative studies must be available for all patients except those with NF1 and LGG (stratum 2) or any patient with optic pathway glioma (stratum 2 or 3), for whom tumor tissue is optional.
• Patients must have received at least one prior chemotherapy or radiation regimen prior to progression.
• At the time of enrollment, at least 6 weeks must have elapsed since the last dose of any nitrosourea, and the longer of 2 weeks or 3 half-lives must have elapsed since the last dose of any other tumor-directed medication. or biologic therapy.
• At least 3 months must have elapsed since the last dose of irradiation to the target tumor(s) at the time of enrollment.
• Patients must be >1 year and <18 years old.
• Performance Score using the Karnofsky Performance Scale (patients > 12 years old) or Lansky Play - Performance Scale (patients ≤ 12 years old) must be ≥ 60 assessed within two weeks prior to enrollment.

• Participants must have normal organ and marrow function as defined below within two weeks prior to enrollment:

  • Absolute neutrophil count > 1,000/mcL
  • Platelets > 75,000/mcL and > 7 days since last platelet transfusion. Hemoglobin > 9 gm/dL and > 7 days since last red blood cell transfusion
  • Not refractory to red cell or platelet transfusions
  • Hepatic: Total bilirubin ≤ 1.5 times the upper limit of normal; SGPT (ALT) and SGOT (AST) < 3 times the institutional upper limit of normal
  • Renal: Serum creatinine which is less than 1.5 time the upper limit of institutional normal for age or GFR > 70 ml/min/1.73m2
  • QTc interval < 450ms
  • Left ventricular ejection fraction (LVEF) > 50% as determined by an echocardiogram
• Female patients of childbearing potential must have negative serum or urine pregnancy test within 72 hours of the first dose of MEK162. Patient must not be pregnant or breast-feeding. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 30 days following cessation of treatment.
• Patient must be able to take oral/enteral medication.
• Patient, parent, or legal guardian must be able to understand and willing to provide informed consent.
• Patients must have recovered from the effects of prior therapy.

Exclusion Criteria

Patients with any of the following characteristics will not be eligible:

• Patients for whom other curative or established standard-of-care therapeutic options with acceptable morbidity exist.
• Patients with any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy.
• History of Gilbert's syndrome
• Patients receiving any other anticancer or experimental drug therapy.
• Use of hematopoietic growth factors within 2 weeks prior to initiation of therapy.
• Any other investigational agents within 2 weeks or ≤ 3 half-lives (whichever is longer) before start of study therapy.
• Patients who have undergone surgery ≤ 3 weeks or who have not recovered from side effects of this procedure prior to receiving study drug.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, impaired gastrointestinal function, or psychiatric illness/social situations that would limit compliance with study requirements.
• History or current evidence of retinal vein occlusion (RVO) or predisposing factors to RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes).
• History of retinal degenerative disease
• Prior therapy with a MEK inhibitor
• Impairment of gastrointestinal function (e.g., active ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
• Patients who have a neuromuscular disorder that is associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
• Patients with uncontrolled hypertension

Inclusion of Women, Minorities, and Other Underrepresented Populations This protocol is open to males and females of all races. See Inclusion Criteria above regarding specific eligibility requirements for female and male patients of child-bearing or child-fathering potential, respectively.

Contacts and Locations

Locations

United States, Alabama

Children's Hospital of Alabama

Birmingham, Alabama, United States, 35233

United States, California

Children's Hospital Los Angeles

Los Angeles, California, United States, 90027

United States, Colorado

Children's Hospital of Colorado

Aurora, Colorado, United States, 80045

United States, District of Columbia

Children's National Heath Systems

Washington, District of Columbia, United States, 20010

United States, Florida

Nicklaus Children's Hospital

Miami, Florida, United States, 33155

United States, Georgia

Children's Healthcare of Atlanta

Atlanta, Georgia, United States, 30322

United States, Maryland

Johns Hopkins University

Baltimore, Maryland, United States, 21287

United States, Massachusetts

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02215

United States, Minnesota

Children's Hospitals and Clinics of Minnesota-Minneapolis

Minneapolis, Minnesota, United States, 55404

United States, Missouri

Washington University School of Medicine

Saint Louis, Missouri, United States, 63110

United States, New York

New York University

New York, New York, United States, 10016

United States, Oregon

Oregon Health and Science University

Portland, Oregon, United States, 97239

United States, Texas

University of Texas Southwestern Medical

Dallas, Texas, United States, 75390

Texas Children's Hospital

Houston, Texas, United States, 77030

United States, Washington

Seattle Children's Hospital

Seattle, Washington, United States, 98145

Sponsors and Collaborators

Children's Hospital Los Angeles

Dana-Farber Cancer Institute

Investigators

• Principal Investigator: Nathan Robison, MD; CHLA

More Information

• Responsible Party: Nathan Robison, M.D., Medical Director of Inpatient Services, Attending Neuro-Oncologist, Associate Professor, Children's Hospital Los Angeles
• ClinicalTrials.gov Identifier: NCT02285439
• Other Study ID Numbers: CHLA-15-00146
• First Posted: November 7, 2014
• Last Update Posted: October 3, 2023
• Last Verified: September 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Nathan Robison, M.D., Children's Hospital Los Angeles:

Pediatric Oncology; Ras/Raf pathway; Low-Grade Glioma; MEK inhibitor

Additional relevant MeSH terms:

Neoplasms; Glioma; Soft Tissue Neoplasms; Brain Neoplasms; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms by Site; Central Nervous System Neoplasms; Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases